|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-8-11
|
|
pubmed:abstractText |
Botulinum neurotoxin type A (BoNT/A) is effective in the treatment of intractable detrusor overactivity (DO). In addition to its known inhibitory effect on presynaptic release of acetylcholine by motor terminals, there is increasing evidence that BoNT/A may affect sensory fibers. We investigated a possible effect of BoNT/A on human bladder afferent mechanisms by studying the sensory receptors P2X3 and TRPV1 in biopsies from patients with neurogenic or idiopathic DO.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Botulinum Toxins, Type A,
http://linkedlifedata.com/resource/pubmed/chemical/Ion Channels,
http://linkedlifedata.com/resource/pubmed/chemical/Neuromuscular Agents,
http://linkedlifedata.com/resource/pubmed/chemical/P2RX3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Purinergic P2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Purinergic P2X3,
http://linkedlifedata.com/resource/pubmed/chemical/TRPV Cation Channels,
http://linkedlifedata.com/resource/pubmed/chemical/TRPV1 protein, human
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0022-5347
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
174
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
977-82; discussion 982-3
|
|
pubmed:dateRevised |
2011-10-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16094018-Adult,
pubmed-meshheading:16094018-Afferent Pathways,
pubmed-meshheading:16094018-Aged,
pubmed-meshheading:16094018-Biopsy,
pubmed-meshheading:16094018-Botulinum Toxins, Type A,
pubmed-meshheading:16094018-Cystoscopy,
pubmed-meshheading:16094018-Dose-Response Relationship, Drug,
pubmed-meshheading:16094018-Female,
pubmed-meshheading:16094018-Humans,
pubmed-meshheading:16094018-Immunoenzyme Techniques,
pubmed-meshheading:16094018-Injections, Intramuscular,
pubmed-meshheading:16094018-Ion Channels,
pubmed-meshheading:16094018-Male,
pubmed-meshheading:16094018-Middle Aged,
pubmed-meshheading:16094018-Muscle Hypertonia,
pubmed-meshheading:16094018-Nerve Fibers,
pubmed-meshheading:16094018-Nerve Fibers, Unmyelinated,
pubmed-meshheading:16094018-Neuromuscular Agents,
pubmed-meshheading:16094018-Receptors, Purinergic P2,
pubmed-meshheading:16094018-Receptors, Purinergic P2X3,
pubmed-meshheading:16094018-Sensitivity and Specificity,
pubmed-meshheading:16094018-Sensory Receptor Cells,
pubmed-meshheading:16094018-Synaptic Transmission,
pubmed-meshheading:16094018-TRPV Cation Channels,
pubmed-meshheading:16094018-Treatment Outcome,
pubmed-meshheading:16094018-Urinary Bladder,
pubmed-meshheading:16094018-Urinary Bladder, Neurogenic,
pubmed-meshheading:16094018-Urinary Incontinence,
pubmed-meshheading:16094018-Urodynamics,
pubmed-meshheading:16094018-Urothelium
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.
|
|
pubmed:affiliation |
Peripheral Neuropathy Unit, Hammersmith Hospital, Imperial College London, United Kingdom.
|
|
pubmed:publicationType |
Journal Article
|
